VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

CEO

ISIN

US92941V3087

Listings

0 Comments

Share your thoughts

FAQ

What is VYNE Therapeutics stock price today?▼

The current price of VYNE.BOATS is $0.6 USD — it has increased by +2.21% in the past 24 hours. Watch VYNE Therapeutics stock price performance more closely on the chart.

What is VYNE Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange VYNE Therapeutics stocks are traded under the ticker VYNE.BOATS.

What is VYNE Therapeutics market cap?▼

Today VYNE Therapeutics has the market capitalization of 19.99M

When is the next VYNE Therapeutics earnings date?▼

VYNE Therapeutics is going to release the next earnings report on May 07, 2026.

What is VYNE Therapeutics revenue for the last year?▼

VYNE Therapeutics revenue for the last year amounts to 1.14M USD.

What is VYNE Therapeutics net income for the last year?▼

VYNE.BOATS net income for the last year is -52.97M USD.

When did VYNE Therapeutics complete a stock split?▼

VYNE Therapeutics has not had any recent stock splits.